

Name of the Issuer:		Jupiter Life Line Hospitals Limited	Last updated on	15-Aug-24												
1	Type of Issue (IPO / FPO)		IPO													
	Source: Prospectus dated September 11, 2023															
2	Issue Size (Rs. Million)*#		8,690.76													
	- Fresh Issue Size (Rs. Millions)		5,420.01													
	- Offer for Sale Component (Rs. Millions)		3,270.75													
	# The Company has, in consultation with the BRLMs, undertaken a private placement of 1,673,469 Equity Shares aggregating to ₹ 1,229.99 million ("Pre-IPO Placement"). The size of the Fresh Issue of Equity Shares has been adjusted to ₹1,229.99 million															
	*Source: Prospectus dated September 11, 2023															
3	Grade of issue along with name of the rating agency															
	Name	Not Applicable														
	Grade	Not Applicable														
	Source: Prospectus dated September 11, 2023															
4	Subscription Level (Number of times)		65.44*													
	*Source: Final post issue report dated September 11, 2023															
	*The above figure is after technical rejections, multiple or duplicate Bids and Bids not banked/returned.															
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges															
	<table><tr><th>Particulars</th><th>%</th></tr><tr><td>(i) allotment in the issue**</td><td>13.50%</td></tr><tr><td>(ii) at the end of 1st Quarter immediately after the listing (September 30, 2023)^</td><td>20.76%</td></tr><tr><td>(iii) at the end of 1st FY (March 31, 2024)^</td><td>21.75%</td></tr><tr><td>(iv) at the end of 2nd FY (March 31, 2025)*</td><td>Not Available</td></tr><tr><td>(v) at the end of 3rd FY (March 31, 2026)*</td><td>Not Available</td></tr></table>				Particulars	%	(i) allotment in the issue**	13.50%	(ii) at the end of 1st Quarter immediately after the listing (September 30, 2023)^	20.76%	(iii) at the end of 1st FY (March 31, 2024)^	21.75%	(iv) at the end of 2nd FY (March 31, 2025)*	Not Available	(v) at the end of 3rd FY (March 31, 2026)*	Not Available
Particulars	%															
(i) allotment in the issue**	13.50%															
(ii) at the end of 1st Quarter immediately after the listing (September 30, 2023)^	20.76%															
(iii) at the end of 1st FY (March 31, 2024)^	21.75%															
(iv) at the end of 2nd FY (March 31, 2025)*	Not Available															
(v) at the end of 3rd FY (March 31, 2026)*	Not Available															
	**As a % of total paid up capital as per prospectus dated September 11, 2023															
	^Holding of institutions category as disclosed to Stock Exchanges															
	*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.															
6	Financials of the issuer															
	(In Rs. Millions)															
	Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*												
	Income from Operations	10,695.00	Not Available	Not Available												
	Net Profit for the period	1,766.12	Not Available	Not Available												
	Paid-up equity share capital	655.66	Not Available	Not Available												
	Reserves excluding revaluation reserves	11,031.73	Not Available	Not Available												
	*Financials not disclosed as reporting for the relevant fiscal year has not been completed.															
7	Trading Status in the scrip of the issuer															
	Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited															
	The Shares have not been suspended or delisted.															
	<table><tr><th>Particulars</th><th>Status</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2024)</td><td>Frequently traded</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2025)*</td><td>Not Available</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2026)*</td><td>Not Available</td></tr></table>				Particulars	Status	(i) at the end of 1st FY (March 31, 2024)	Frequently traded	(ii) at the end of 2nd FY (March 31, 2025)*	Not Available	(iii) at the end of 3rd FY (March 31, 2026)*	Not Available				
Particulars	Status															
(i) at the end of 1st FY (March 31, 2024)	Frequently traded															
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available															
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available															
	*Trading status not disclosed as the relevant fiscal year has not been completed.															
	Source: Stock exchange data.															
8	Change in Directors of issuer from the disclosures in the offer document															
	Particulars	Name of the Director	Appointed / Resigned													
	(i) at the end of 1st FY (March 31, 2024)*	-	-													
	(ii) at the end of 2nd FY (March 31, 2025)*#	Mr. Amar Manjrekar	Appointed													
		Dr. Ajay Thakker	Reappointed													
	(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available													
	* Changes in Directors not disclosed as the relevant fiscal year has not been completed.															
	# Updated till August 15, 2024															

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable*
(ii) Actual implementation	Not applicable*
(iii) Reasons for delay in implementation, if any	Not applicable*
*The Company did not undertake any project	

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

Estimated Utilisation of Net Proceeds and the Pre-IPO Placement

Particular	Amount to be funded from the Net Proceeds	Fiscal 2024	Fiscal 2025	Fiscal 2026
Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55	-	-
General Corporate Purpose	11.63	11.63	-	-
Total (1)	5,113.18	5,113.18		
Sourced from Prospectus dated September 11, 2023				

(ii) Actual utilization

Actual Utilisation of Net Proceeds and the Pre-IPO Placement

Particular	Fiscal 2024 [#]	Fiscal 2025	Fiscal 2026
Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	Not Available	Not Available
General Corporate Purpose	11.63	Not Available	Not Available

[#] As per report issued by Monitoring agent dated May 10, 2024

(iii) Reasons for deviation, if any Not Applicable

11 Comments of monitoring agency

(a) Comments on use of funds Not Applicable*

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document No Deviation*

(c) Any other reservations expressed by the monitoring agency about the end use of funds Nil*

*Report issued by Monitoring agent dated May 10, 2024

12 Pricing Data

Issue Price (Rs.): 735
Designated Stock Exchange: NSE
Listing Date: 18-Sep-23

Price parameters	At close of listing day (September 18, 2023)	At close of 30th calendar day from listing day (October 17, 2023) ⁽¹⁾	At close of 90th calendar day from listing day (December 16, 2023) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	1,075.75	1045.65	1,150.60	1,192.70	1,653.95	970.00
NIFTY 50 ⁽⁶⁾	20,133.30	19811.50	21,456.65	22,462.00	22,526.60	17,312.75
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽³⁾⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2026) ⁽³⁾⁽⁴⁾		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 ⁽⁶⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Source: NSE website

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant period/ fiscal year has not completed

(5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.

(6) Comparable Sectoral index is not available

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025) ⁽²⁾	At the end of 3rd FY (March 31, 2026) ⁽²⁾
EPS (Basic)	Issuer:			
	Consolidated (Basic)	13.95	28.65	Not Available
	Consolidated (Diluted)	12.95	28.65	Not Available
	Peer Group: (Diluted)			
	Apollo Hospitals Enterprise Limited	Basic - 56.97 Diluted - 56.97	Basic - 70.28 Diluted - 70.28	Not Available
	Fortis Healthcare Limited	Basic - 7.80 Diluted - 7.80	Basic - 2.64 Diluted - 2.64	Not Available
	Max Healthcare Institute Limited	Basic - 11.38 Diluted - 11.36	Basic - 7.07 Diluted - 7.05	Not Available
	Narayana Hrudayalaya Limited	Basic - 29.85 Diluted - 29.85	Basic - 20.90 Diluted - 20.90	Not Available
	Global Health Limited	Basic - 12.58 Diluted - 12.57	Basic - 17.80 Diluted - 17.80	Not Available
	Krishna Institute of Medical Sciences Limited	Basic - 42.03 Diluted - 42.03	Basic - 29.41 Diluted - 29.41	Not Available
	Industry Avg:	N.A.	N.A.	N.A.
Price to Earnings Ratio (P/E)	Issuer:			
	Consolidated (Basic)	56.76	41.63	Not Available
	Consolidated (Diluted)	56.76	41.63	Not Available
	Peer Group (Consolidated)			
	Apollo Hospitals Enterprise Limited	Basic - 84.64 Diluted - 84.64	Basic - 91.82 Diluted - 91.82	Not Available
	Fortis Healthcare Limited	Basic - 40.26 Diluted - 40.26	Basic - 162.25 Diluted - 162.25	Not Available
	Max Healthcare Institute Limited	Basic - 45.97 Diluted - 45.97	Basic - 115.21 Diluted - 115.54	Not Available
	Narayana Hrudayalaya Limited	Basic - 33.14 Diluted - 33.14	Basic - 61.89 Diluted - 61.89	Not Available
	Global Health Limited	Basic - 53.70 Diluted - 53.70	Basic - 74.69 Diluted - 74.69	Not Available
	Krishna Institute of Medical Sciences Limited	Basic - 45.09 Diluted - 45.09	Basic - 69.54 Diluted - 69.54	Not Available
	Industry Avg:	50.47	N.A.	N.A.
RoNW(%)	Issuer:			
	Consolidated	20.03%	15.11%	Not Available
	Peer Group: (Consolidated)			
	Apollo Hospitals Enterprise Limited	16.40%	13.10%	Not Available
	Fortis Healthcare Limited	20.90%	2.19%	Not Available
	Max Healthcare Institute Limited	62.80%	8.95%	Not Available
	Narayana Hrudayalaya Limited	35.40%	27.36%	Not Available
	Global Health Limited	16.20%	16.45%	Not Available
	Krishna Institute of Medical Sciences Limited	25.70%	12.61%	Not Available
	Industry Avg:	N.A.	N.A.	N.A.

NAV per Equity Share

Issuer:				
Consolidated	64.39	178.25	Not Available	Not Available
Peer Group: (Consolidated)				
Apollo Hospitals Enterprise Limited	378.33	536.28	Not Available	Not Available
Fortis Healthcare Limited	46.67	120.37	Not Available	Not Available
Max Healthcare Institute Limited	24.14	79.03	Not Available	Not Available
Narayana Hrudayalaya Limited	90.5	90.05	Not Available	Not Available
Global Health Limited	90.35	108.21	Not Available	Not Available
Krishna Institute of Medical Sciences Limited	193.96	233.23	Not Available	Not Available
Industry Avg:	N.A	N.A	N.A	N.A.

(1) Prospectus dated September 11, 2023

(2) Information not provided as the relevant fiscal year has not completed

Source:

* All the financial information for the Company above is sourced from the Restated Summary Statement

**Information for the industry peers mentioned above is on a consolidated basis and is sourced/derived from the respective annual results for the year ended March 31, 2023 of such industry peers available on the website of stock exchange

Notes:

1) Earnings per share (Basic) = Restated net profit after tax, available for equity shareholders/Weighted average number of equity shares outstanding during the period/year.

2) Earnings per share (Diluted) = Restated profit for the period/year / Weighted average number of diluted potential equity shares

3) Return on Net Worth (For Jupiter Life Line Hospitals Limited) (%) = Restated net profit after tax / Restated Net Worth at the end of the

4) Return on Net Worth (For listed industry peers) (%) = Profit after tax / Tangible Net Worth.

5) Net Worth means the aggregate value of the paid-up share capital and all reserves created out of the profits, securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amortisation in accordance with Regulation 2(1)(hh) of the SEBI ICDR Regulations.

6) Tangible net worth = Total Net Worth – Intangible assets.

7) Net asset value per share (For Jupiter Life Line Hospitals Limited) (in ₹) = Restated Net Worth at the end of the period/year / Number

8) Net asset value per share (For listed industry peers) = Tangible Net Worth as at end of the period/year / Number of equity shares

9) Operating income = Gross sales + Other related income.

10) P/E is calculated basis closing market price of equity shares from NSE divided by diluted by the diluted earnings per share.

14 Any other material information

Date of disclosure	Announcement
18-Sep-23	Trading Members of the Exchange are hereby informed that effective from September 18, 2023, the equity shares of Jupiter Life Line Hospitals Ltd (Scrip Code: 543980) are listed and admitted to dealings on the Exchange in the list of "B" Group Securities. For further details please refer to the notice no 20230915- dated September 15, 2023.
20-Sep-23	The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for <u>SBI Mutual Funds</u>
29-Sep-23	Closure of Trading Window
30-Sep-23	Board Meeting Intimation for Notice Of Board Meeting To Be Held On Friday October 6, 2023 to Consider And Approve The Unaudited Financial Results Along With Limited Review Report Of The Company For The Quarter Ended June 30, 2023 Under Regulation 33 Of The Sebi Listing
6-Oct-23	Outcome Of The Board Meeting Held On Friday, 6Th October ,2023
6-Oct-23	Announcement under Regulation 30 (LODR)-Investor Presentation
6-Oct-23	Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('LODR Regulations') Read With Schedule III Of LODR Regulations And Offer Letter Dated September 11, 2023
8-Oct-23	Newspaper Publication for Unaudited Financial Results(Standalone and Consolidated) for quarter ended 30th June,2023
16-Oct-23	Compliance certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for Quarter ended 30th September, 2023
2-Nov-23	Jupiter Life Line Hospitals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 ,inter alia, to consider and approve the Un-audited Financial Results along with the Limited Review Report of the Company for the quarter and half year ended September 30, 2023 under Regulation 33 of the SEBI Listing Regulation
10-Nov-23	Board Meeting Outcome For The Quarter And Half Year Ended September 30, 2023
10-Nov-23	Investor Presentation for the quarter and half year ended September 30, 2023
10-Nov-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
10-Nov-23	Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
12-Nov-23	Announcement under Regulation 30 (LODR)-Newspaper Publication
21-Nov-23	Q2 & H1 FY24 Earnings Conference Call- Transcript
29-Dec-23	INTIMATION OF TRADING WINDOW CLOSURE FOR THE QUATER AND NINE MONTHS ENDED ON 31 DECEMBER, 2023
29-Dec-23	Jupiter Life Line Hospitals Limited-543980-Closure of Trading Window - XBRL
11-Jan-24	Pursuant to Reg 74(5) of SEBI (DP) Regulation we are filing the certificate received from RTA for the quarter ended 31st December, 2023
16-Jan-24	Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India ("SEBI") (Listing Obligations And Disclosure Requirements
18-Jan-24	Intimation Under Regulation 8 Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015.
1-Feb-24	Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Along With The Limited Review Report Of The Company

1-Feb-24	Jupiter Life Line Hospitals Limited-543980-Closure of Trading Window - XBRL
9-Feb-24	Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, February 9, 2024
9-Feb-24	Outcome Of The Board Meeting Held On Friday, February 9, 2024
9-Feb-24	Intimation Of Resignation Of Internal Auditor
9-Feb-24	Intimation Of Appointment Of Internal Auditor
9-Feb-24	Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
9-Feb-24	Announcement under Regulation 30 (LODR)-Investor Presentation
9-Feb-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11-Feb-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Feb-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
22-Feb-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure
27-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Credit Rating
28-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider
28-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window
6-Apr-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants)
2-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to inter-alia consider and
2-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window
7-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider Dividend.
10-May-24	Dr. Ankit Ajay Thakker has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of
10-May-24	Jupiter Life Line Hospitals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange that Board of Directors at its meeting held on May 10, 2024, recommended Final
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding 'addition of 75 beds in existing Indore Hospital and 22 beds in existing Pune
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about change in Management - Appointment of Secretarial Auditor
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about change in Management - Appointment of Cost Auditor
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Change in Director(s) of the company.
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Change in Director(s) of the company.
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
10-May-24	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and 41(4) of SEBI (Issue of Capital and
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Investor Presentation
10-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 10-May-2024 for Dividend
10-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance
12-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Copy of Newspaper Publication of Financial Results for quarter and year ended
13-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Link of Recording
17-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Transcript of the Q4 & FY24 Results Conference Call
23-May-24	Compliances-Reg.24(A)-Annual Secretarial Compliance
26-Jun-24	Closure of Trading Window
12-Jul-24	Fixation Of Record Date For The Purpose Of Final Dividend For The Financial Year 2023-24
12-Jul-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
12-Jul-24	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15-Jul-24	Reg. 34 (1) Annual Report.
15-Jul-24	Notice Of 22Nd AGM To Be Held On August 09, 2024
15-Jul-24	Business Responsibility and Sustainability Reporting (BRSR)
16-Jul-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
1-Aug-24	Intimation Under Regulation 30 Of Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015- Resignation Of Statutory Auditors Of Material Subsidiary
5-Aug-24	Board Meeting Intimation for Board Meeting Intimation For To Consider And Approve The Un-Audited Financial Results Along With The Limited Review Report Of The Company (Standalone And Consolidated) For The Quarter Ended June 30, 2024
9-Aug-24	Board Meeting Outcome for Outcome Of Board Meeting Dated August 09, 2024
9-Aug-24	Unaudited Financial Results Along With Limited Review Report June 30, 2024
9-Aug-24	Announcement under Regulation 30 (LODR)-Change in Management
9-Aug-24	Announcement under Regulation 30 (LODR)-Change in Management
9-Aug-24	Announcement under Regulation 30 (LODR)-Change in Directorate
9-Aug-24	Announcement under Regulation 30 (LODR)-Investor Presentation
9-Aug-24	Shareholder Meeting / Postal Ballot-Outcome of AGM
9-Aug-24	Shareholder Meeting / Postal Ballot-Scrutinizer's Report
11-Aug-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
12-Aug-24	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14-Aug-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Source: www.bseindia.com

Note: The Company would meet Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.